Treace Medical Concepts Inc(TMCI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.93 | Insider Own | 26.81% | Shs Outstand | 65.2M | Perf Week | -7.27% |
| Market Cap | 0.29B | Forward P/E | - | EPS next Y | 8.78% | Insider Trans | 2.51% | Shs Float | 47.6M | Perf Month | -4.74% |
| Enterprise Value | 0.32B | PEG | - | EPS next Q | -0.25 | Inst Own | 49.76% | Short Float | 3.28% | Perf Quarter | 15.73% |
| Income | -0.06B | P/S | 1.43 | EPS this Y | 8.65% | Inst Trans | -9.63% | Short Ratio | 2.49 | Perf Half Y | 235.19% |
| Sales | 0.21B | P/B | 4.36 | EPS next 5Y | 9.25% | ROA | -30.72% | Short Interest | 1.56M | Perf YTD | 84.69% |
| Book/sh | 1.04 | P/C | 6.45 | EPS past 3/5Y | -6.38% -61.76% | ROE | -71.99% | 52W High | -40.53% ($7.61) | Perf Year | -39.18% |
| Cash/sh | 0.7 | P/FCF | - | Sales past 3/5Y | 14.46% 29.96% | ROIC | -43.48% | 52W Low | 286.75% ($1.17) | Perf 3Y | -68.13% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -17.9% | Gross Margin | 79.45% | Volatility(W/M) | 5.34% 5.88% | Perf 5Y | -83.44% |
| Dividend TTM | - | EV/Sales | 1.57 | Sales Y/Y TTM | -3.95% | Oper. Margin | -26.17% | ATR (14) | 0.28 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.95 | EPS Q/Q | 11.63% | Profit Margin | -28.99% | RSI (14) | 49.19 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.9 | Sales Q/Q | -4.24% | SMA20 | -1.6% ($4.6) | Beta | 1.49 | Target Price | $5.5 |
| Payout | - | Debt/Eq | 1.08 | Earnings | 2026/8/7 | SMA50 | 1.06% ($4.48) | Rel Volume | 0.23 | Prev Close | $4.35 |
| Employees | 450 | LT Debt/Eq | 1.02 | EPS/Sales Surpr. | 19.46% 3.08% | SMA200 | 53.4% ($2.95) | Avg Volume(3M) | 0.63M | Price | $4.53 |
| IPO | 2021/4/23 | Option/Short | Yes/Yes | Trades | 2049 | Volume | 146,858 | Change | 4.02% |
Company
TMCI is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US medical device company that develops and supplies surgical devices for foot and ankle correction, including those used for hallux valgus (bunions) and other related procedures. The company has grown in the foot and ankle orthopedic market by centering its operations around its flagship product, the Lapiplasty 3D Bunion Correction System, while also providing surgeon education and surgical solutions.
Over the past 1 year, roughly in the middle
40% below its 1-year high.
TMCI has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +8.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -68.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 49.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
VTWG 0.00%
DFAS 0.00%
HDG 0.00%
HONG 0.00%It ranks #4 in the industry
Based on market cap of $294M.
TMCI $294M PER -
ABT $176B PER 33.0
MDT $116B PER 22.4
SYK $106B PER 28.6
FAQ
What kind of company is TMCI?
TMCI belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of TMCI?
The market cap of TMCI is approximately $294M, ranking 3,746 within its sector.
What is the 52-week high and low for TMCI?
TMCI has recorded a 52-week high of $7.61 and a low of $1.17.
